2006 Annual Meeting | Non-Alzheimer's Dementia

Date Monday 04/03/06

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Jeffrey L. Cummings, MD, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to identify the key clinical features of the principal non-Alzheimer's dementias, know how to pursue a comprehensive diagnostic evaluation, and understand the available therapies.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
02:15 PM - 03:00 PM		Vascular Dementia Charles S. DeCarli, MD, FAAN
03:00 PM - 03:45 PM		Dementia with Lewy Bodies Daniel Kaufer, MD, FAAN
03:45 PM - 04:00 PM		Break
04:00 PM - 04:45 PM		Frontotemporal Dementias Bruce L. Miller, MD, FAAN
04:45 PM - 05:30 PM		Approach to the Differential Diagnosis of Dementias Jeffrey L. Cummings, MD, FAAN
05:30 PM - 06:00 PM		Questions and Answers

Faculty Disclosures
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Charles S. DeCarli, MD, FAAN	Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. DeCarli has received research support from NIH.
Bruce L. Miller, MD, FAAN	Dr. Miller has nothing to disclose.
Daniel Kaufer, MD, FAAN	No disclosure on file

��ɫ��

��ɫ��